REMICADE® (infliximab)
AXERT® (almotriptan malate) Tablets
CONCERTA® (methylphenidate HCI) Extended-Release Tablets CII
DITROPAN XL® (oxybutynin chloride)
DITROPAN XL®
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA SUSTENNA®
INVOKAMET™ (canagliflozin/metformin HCl) tablets
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
NUCYNTA® (tapentadol)
NUCYNTA® ER (tapentadol extended-release tablets)
NUCYNTA® ER
OLYSIO® (simeprevir)
ONETOUCH® Meters and Test Strips
ORTHO TRI-CYCLEN® LO (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® LO
PANCREAZE® (pancrelipase) Delayed-Release Capsules
PARAFON FORTE® DSC (chlorzoxazone)
PARAFON FORTE® DSC
PREZCOBIX™ (darunavir 800 mg/ cobicistat 150 mg) tablets
PREZISTA® (darunavir) Tablets
PROCRIT® (epoetin alfa)
RAZADYNE® (galantamine)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab) for infusion
SIMPONI ARIA®
SPORANOX® (itraconazole)
STELARA® (ustekinumab)
SYLVANT™ (siltuximab)
TERAZOL® (terconazole)
TOPAMAX® (topiramate) Tablets
ULTRACET® (tramadol hydrochloride/acetaminophen)
ULTRAM® (tramadol hydrochloride)
ULTRAM® ER (tramadol HCI) Extended-Release Tablets
ULTRAM® ER
XARELTO® (rivaroxaban)
ZYTIGA® (abiraterone acetate)

Need help paying for your REMICADE® (infliximab) prescription?

We want to guide you to programs that may help. Here you'll find the financial assistance programs available for REMICADE®. We have also listed most of the eligibility requirements for each so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their web sites to learn more.

RemiStart®

1-888-222-3771

Monday-Friday, 8 AM to 8 PM ET

To view programs that are best suited for you, select your insurance status for REMICADE® or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for REMICADE® or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

This program is affiliated with Janssen.

It's updated on a regular basis. Be sure to visit the program site for additional information.

RemiStart® Patient Rebate Program for REMICADE®

The RemiStart® Patient Rebate Program may provide a rebate for your out-of-pocket REMICADE® costs. If eligible, you will pay $5 per infusion and will receive a rebate for your medication out-of-pocket costs for up to $10,000 or 12 months from your first eligible date of service, whichever comes first. You may re-enroll annually to continue receiving a benefit from the program.

View application requirements

Eligibility Requirements for RemiStart®

You may be eligible if:

  • You have been prescribed REMICADE®
  • You have private/commercial insurance coverage for REMICADE®
  • Additional restrictions apply

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to medicines for uninsured patients who lack the financial resources to pay for them. If you need REMICADE® (infliximab), and are uninsured and unable to pay for your medicine, please contact a JJPAF program specialist at 1-800-652-6227 9 AM to 6 PM ET or visit the foundation website at JJPAF.org to see if you might qualify for assistance.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Savings Program

Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and co-insurance. Find out if your state has a program that can help you.

Medicare Part D Extra Help — Low-Income Subsidy

Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.

Those who are eligible for LIS may:

  • Receive assistance paying their monthly premium
  • Have a reduced or no deductible
  • Have reduced or no prescription co-insurance and co-payments
  • Have no gap in coverage

Chronic Disease Fund

This foundation provides financial assistance to those eligible for co-pays and travel costs associated with treatment.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Crohn's Disease, Plaque Psoriasis

Patient Access Network Foundation

This foundation provides financial assistance to those eligible for their out-of-pocket medication expenses.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Ankylosing Spondylitis, Crohn's Disease, Plaque Psoriasis, Rheumatoid Arthritis

Patient Advocate Foundation

This foundation provides financial assistance to those eligible for their out-of-pocket medication expenses.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Ankylosing Spondylitis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis

The Assistance Fund

This program offers financial assistance for co-pays, premiums, and basic healthcare needs for those eligible.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis

The HealthWell Foundation®

This foundation provides financial assistance to those eligible for co-insurance, co-payments, healthcare premiums and deductibles for certain medications.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Ankylosing Spondylitis, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis
January 20, 2015
Expand
Expand

IMPORTANT SAFETY INFORMATION

INDICATIONS

REMICADE®, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

REMICADE® is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.

REMICADE® is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

REMICADE® is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

REMICADE® is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.

REMICADE® is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

REMICADE® is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

REMICADE® is indicated for the treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. REMICADE® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Only your doctor can recommend a course of treatment after checking your health condition. REMICADE® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE®.

Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. Hepatosplenic T-cell lymphoma, a rare form of fatal lymphoma, has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE® and azathioprine or 6-mercaptopurine. For children and adults taking TNF blockers, including REMICADE®, the chances of getting lymphoma or other cancers may increase.

You should discuss any concerns about your health and medical care with your doctor.

What should I tell my doctor before I take REMICADE®?

You should let your doctor know if you have or ever had any of the following:

Also tell your doctor if you:

What should I watch for and talk to my doctor about before or while taking REMICADE®?

The following serious (sometimes fatal) side effects have been reported in people taking REMICADE®.

You should tell your doctor right away if you have any of the signs listed below:

Please read the Medication Guide for REMICADE® and discuss it with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

005912-131106

IMPORTANT SAFETY INFORMATION

INDICATIONS

REMICADE®, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

REMICADE® is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.

REMICADE® is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

REMICADE® is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

REMICADE® is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.

REMICADE® is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

REMICADE® is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

REMICADE® is indicated for the treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. REMICADE® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Only your doctor can recommend a course of treatment after checking your health condition. REMICADE® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE®.

Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. Hepatosplenic T-cell lymphoma, a rare form of fatal lymphoma, has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE® and azathioprine or 6-mercaptopurine. For children and adults taking TNF blockers, including REMICADE®, the chances of getting lymphoma or other cancers may increase.

You should discuss any concerns about your health and medical care with your doctor.

What should I tell my doctor before I take REMICADE®?

You should let your doctor know if you have or ever had any of the following:

Also tell your doctor if you:

What should I watch for and talk to my doctor about before or while taking REMICADE®?

The following serious (sometimes fatal) side effects have been reported in people taking REMICADE®.

You should tell your doctor right away if you have any of the signs listed below:

Please read the Medication Guide for REMICADE® and discuss it with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

005912-131106